Skip to content
Company Analysis

Harrow, Inc. HROW

A comprehensive view of key metrics, scores, and financial health for Harrow, Inc.

Overview of Harrow, Inc.

HROW NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Harrow, Inc. (HROW), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $41.88, about 64.4% overvalued vs fair value, +28.1% 1Y return, ranked 808/1145 in sector.
Metrics Rev Growth 36.4% ROE -8.4% Gross Margin 75.1%
USD 41.88
-4.19%
(Delayed)
• Vol 90d: 65.2%
52-Week Range
Market Cap
$1.60B
Enterprise Value
$1.81B
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 86%
Updated: Jul 5
Top Beats

Quick Facts

Website https://www.harrow.com
HQ Nashville, TN
Employees 382
Fiscal year Dec 31

Next Events

Earnings Aug 10 Estimated

Fair Value Snapshot

Bear Base Bull
$14
$15
$16
Current: $41.88 -64% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$272.3M
36.4%%
Gross Profit
$204.4M
35.9%%
R&D Expense
$20.9M
71.2%%
Operating Income (EBIT)
$22.8M
317.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
192.3%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
3/4
Improving
0
High Impact
1
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Harrow, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
62
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
74
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 95% Coverage
Trade-Off Triangle Visualization A ternary plot showing HROW's balance between Growth (44.7%), Profitability (33.4%), and Safety (21.9%). Growth 45% Safety 22% Profitability 33%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

83th percentile vs peers
83
Key Signals
Rev Growth YoY 36.4% 87p Revenue CAGR 3Y 45.4% 87p EPS Growth YoY 71.5% 63p TSR 5.02 97p
Strengths
  • Growth performance in top 20% of peers (percentile: 83)
  • Rev Growth YoY in top 20% of peers (36.4%, 87th percentile)
  • Revenue CAGR 3Y in top 20% of peers (45.4%, 87th percentile)
  • TSR in top 20% of peers (5.02, 97th percentile)
Risks

No significant risks identified for this axis.

Profitability

62th percentile vs peers
62
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

40th percentile vs peers
41
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Harrow, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$14.91
- - -
-64.4% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000